Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351766 · ClinicalTrials.gov registry record · Phase 3
Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation
A Phase 3 study, sponsored by University of Maryland, College Park.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT01351766: Completed Phase 3 study, sponsored by University of Maryland, College Park.
NCT01351766 is a Phase 3 study that has completed, run by University of Maryland, College Park. The registered enrollment target is 39 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01351766, a Phase 3 study, has completed, sponsored by University of Maryland, College Park.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
The primary purpose of this study is to develop a specialized behavioral activation treatment for smoking in youths ages 18-21 with elevated depressive symptoms. In the first phase we utilize focus groups and pilot testing with 15 youths to develop the behavioral activation smoking treatment for youth. In Phase II, we will conduct an open-label trial of the new treatment that will include 8 weeks of transdermal nicotine patch, which will begin at the time of quitting smoking. Participants will be followed over 26 weeks post-quit date. A subset of participants will also undergo an fMRI session to examine reward sensitivity.
Primary Outcome
7 days of smoking abstinence confirmed via expired carbon monoxide at 12 weeks
Interventions
- DRUG Transdermal Nicotine Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01351766 record still lists
NCT01351766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Transdermal Nicotine Patch is the first listed.
NCT01351766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01351766 about?
NCT01351766 is a clinical study titled "Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation". The primary purpose of this study is to develop a specialized behavioral activation treatment for smoking in youths ages 18-21 with elevated depressive symptoms. In the first phase we utilize focus groups and pilot testing with 15 youths to develop the behavioral activation smoking treatment for you...
What is the current status of trial NCT01351766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2010-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01351766?
The interventions under investigation include: Transdermal Nicotine Patch (DRUG).
Who is sponsoring clinical trial NCT01351766?
This trial is sponsored by University of Maryland, College Park, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01351766's enrollment target sits among peer trials
39 1898th of 2000 higher than 101 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia